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Abstract: Alzheimer’s disease (AD) is a major cause of the rapidly growing and crushing aging 
challenge that threatens to economically undermine today’s healthcare system. AD preva-
lence will grow to over 100 million cases in 2050. AD is incurable but can be prevented. There-
fore, the most viable solution may be to detect very early signs of AD (presymptomatically) 
in citizens-at-risk and to intervene in time to reduce AD risk or prevent it entirely. The present 
project will refine and validate two breakthrough innovations for AD detection and AD pre-
vention and commercialize them as a one-stop digital medical device, named ‘AD Detect & 
Prevent’. The first innovation is a highly sensitive cognitive assessment method recently pio-
neered by a group of researchers that has been shown to detect subtle presymptomatic 
stage cognitive decline specific to AD. This will be integrated with the second innovation – a 
digital AD prevention programme delivered on an award-winning computerized cognitive 
training and rehabilitation platform (app + web) that uses high intensity immersive and adap-
tive ‘neurogames’ and audio-based therapy for behavioural intervention, designed for 
strengthening core cognitive functions, building cognitive reserve, changing lifestyle and thus 
reducing the overall AD risk in individuals. The detection and prevention methods will un-
dergo vigorous scientific validation, and the ambition is to create and become the global 
standard of care for precise presymptomatic detection of AD and effective AD prevention.  
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Introduction 
To date, AD is incurable. However, scientific studies indicate that 1/3 of all AD cases could 
be prevented if effective interventions happen before disease onset (Barnes et al., 2009). 
This is significant because a 5-year onset delay could result in 41% lower prevalence by 
2050 (Zissimopoulos, Crimmins, & St.Clair, 2014). Therefore, timely detection of AD is key. 
However, the main challenge in early AD detection today is that current methods are unable 
to detect the earliest signs of cognitive changes that are so subtle that both the individual 
and standardized clinical neuropsychological assessments are unable to pick up before the 
symptomatic phase, thus delaying detection by decades (Rajan, Wilson, Weuve, Barnes, & 
Evans, 2015). The present project discovered groundbreaking innovations to address these 
challenges of AD and aims to deliver an integrated AD solution that offers presymptomatic 
detection and effective prevention.  
In respect of presymptomatic AD detection, recently, a group of researchers at the Univer-
sity of Oxford developed a set of highly sensitive cognitive tests of working memory (WM, 
one of the first cognitive domains to be affected in early-stage AD) that can identify individu-
als highly susceptible to developing AD but are currently free of clinical symptoms (Liang et 
al., 2016). These cognitive detection tests will be gamified and further validated in the pre-
sent project. In the short term, this detection method can be used in high-risk population 
segments where the need is the most acute. If this detection method is applied to high AD 
risk individuals and the aging population at scale in the long term, it could hold a tremen-
dous potential for enabling prevention and slowing the progression of AD in early-stage pa-
tients. 
In terms of presymptomatic AD prevention, a well-established, novel and innovative digital 
platform designed for computerized cognitive training and neurorehabilitation has been 
shown to be able to create significant cognitive and behavioural improvements in various 
population segments. It could be an effective way to prevent or delay AD onset since scien-
tific studies have documented the great potential for preventing AD using these methods 
(Paillard, Rolland, & de Souto Barreto, 2015; Shah, 2013). 
Integrating presymptomatic AD detection and prevention into a specialized ‘AD Detect-Pre-
vent’ solution that targets populations-at-risk and elderlies could have a massive impact on 
the population-wide outlook for AD trajectory (Zissimopoulos et al., 2014). In practice, offer-
ing the solution in an easily accessible and user-friendly digital app and web format makes it 
highly scalable. 
The integrated ‘AD Detect-Prevent’ solution will subsequently undergo empirical and clinical 
validation. Three vigorous behavioural and neuroimaging studies are designed to examine 
the precision and validity of the AD detection tool, and the efficacy of the AD prevention 
programme. 
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Description of design proposal 
Scientifically, at the heart of the proposed AD solution is a ‘graded’ cognitive assessment 
test named the ‘what was where’ task (Figure 1) (Liang et al., 2016). It is based on the princi-
ple that humans experience the world in a ‘graded’ rather than dichotomous manner. The 
‘graded’ model and method of assessing WM has received much solid scientific support and 
demonstrated that it is a more sensitive indicator of AD than standardized clinical tests. 
When gamified and integrated into a well-established digital platform, this assessment 
method will become universally available and offers an affordable and validated tool to aid 
presymptomatic AD detection.  
 
Figure 1  The ‘what was where’ task where one or three fractals are presented on a touchscreen, after a variable 
delay one of the items returns with a foil. Participants touch the item they recall and drag it to its re-
membered location. Using this task, researchers discovered that while performance on item identifica-
tion and location recall was comparable, misbinding errors/swaps were increased in asymptomatic car-
riers of amyloid precursor protein gene mutation compared to age-matched controls without the gene 
mutation. Reprinted from “Visual short-term memory binding deficit in familial Alzheimer’s disease”, by 
Liang et al. 2016. 
The technical product foundation of the proposed solution is a digital platform, designed for 
cognitive training and rehabilitation. The platform uses high intensity immersive, personal-
ized neurogames and audio-based digital therapy for behavioural modifications, and it is de-
signed to strengthen core cognitive functions, build cognitive reserve and change unhealthy 
lifestyle. These activities are packaged into easy-to-follow programmes and a highly intuitive 
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user interface (Figure 2). During the project, the ‘graded’ cognitive assessment methods will 
be gamified and integrated into the digital platform. Based on each user’s assessment out-
come, a tailored AD prevention programmes will subsequently be offered. They are highly 
personalized and intensive, exercise multiple cognitive domains simultaneously, are highly 
motivating and engaging, and are continuously adaptive as training progresses. 
 
Figure 2   Illustrations of the digital platform based on which  
the integrated AD detection and prevention solution will be delivered. 
Complementary data description 
Complementary data consists of illustrations of the digital platform and its existing neuro-
games. 
Acknowledgements:  
This project is funded by the Horizon2020 – Fast Track to Innovation Scheme. 
References 
Barnes, D. E., Yaffe, K., Belfor, N., Jagust, W. J., DeCarli, C., Reed, B. R., & Kramer, J. H. (2009). Computer-based Cognitive Training for Mild 
Cognitive Impairment: Results from a Pilot Randomized, Controlled Trial. Alzheimer Disease & Associated Disorders, 23(3), 205–210. 
https://doi.org/10.1097/WAD.0b013e31819c6137 
Liang, Y., Pertzov, Y., Nicholas, J. M., Henley, S. M. D., Crutch, S., Woodward, F., … Husain, M. (2016). Visual short-term memory binding 
deficit in familial Alzheimer’s disease. Cortex, 78, 150–164. https://doi.org/10.1016/j.cortex.2016.01.015 
Paillard, T., Rolland, Y., & de Souto Barreto, P. (2015). Protective Effects of Physical Exercise in Alzheimer’s Disease and Parkinson’s Disease: A 
Narrative Review. Journal of Clinical Neurology, 11(3), 212. https://doi.org/10.3988/jcn.2015.11.3.212 
Rajan, K. B., Wilson, R. S., Weuve, J., Barnes, L. L., & Evans, D. A. (2015). Cognitive impairment 18 years before clinical diagnosis of Alzheimer 
disease dementia. Neurology, 85(10), 898–904. https://doi.org/10.1212/WNL.0000000000001774 
Shah, R. (2013). The Role of Nutrition and Diet in Alzheimer Disease: A Systematic Review. Journal of the American Medical Directors 
Association, 14(6), 398–402. https://doi.org/10.1016/j.jamda.2013.01.014 
Zissimopoulos, J., Crimmins, E., & St.Clair, P. (2014). The Value of Delaying Alzheimer’s Disease Onset. Forum for Health Economics and 
Policy, 0(0). https://doi.org/10.1515/fhep-2014-0013 
